Javier Martin-Broto, Sarcoma Medical Oncologist at the University Hospital Jiménez Díaz Foundation, shared an article by Carlos Torrado, et al. on LinkedIn:
“Pazopanib’s activity in Malignant Granular Cell Tumors is showing some serious promise, with a response rate of 40% based on RECIST criteria and an 80% disease control rate.
That’s a big deal—actually, it’s the highest RECIST activity we’ve seen with pazopanib in the sarcoma space.
Given that this is an ultra-rare disease, I think it’s worth getting the word out about this compilation brilliantly put together by Dr. Carlos Torrado, now at MD Anderson Cancer Center in Houston, Texas.”
Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature.
Journals: Cancers by MDPI
Authors: Carlos Torrado, et al.
More posts featuring Javier Martin-Broto.